Denali Therapeutics

DNLIPhase 3

Denali Therapeutics is a public biotech company focused on discovering, developing, and delivering medicines for serious diseases, with a particular emphasis on crossing biological barriers to reach the brain. The company's proprietary TransportVehicle™ platform is central to its strategy, aiming to transform treatment for neurodegenerative and lysosomal storage disorders. Denali has built a diverse clinical-stage pipeline through both internal R&D and strategic partnerships, positioning itself at the forefront of next-generation CNS therapeutics. The company is headquartered in South San Francisco, California, and trades on the NASDAQ under the ticker DNLI.

Market Cap

$3.2B

Employees

300-500

Focus

AntibodiesBiologics

DNLI · Stock Price

USD 20.1713.03 (-39.25%)

Historical price data

AI Company Overview

Technology Platform

The TransportVehicle™ (TV) platform is a proprietary technology engineered to facilitate the delivery of large molecule therapeutics across the blood-brain barrier and other biological barriers via receptor-mediated transcytosis, enabling treatment of diseases affecting the brain and central nervous system.

Pipeline Snapshot

17 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
tividenofusp alfa	Mucopolysaccharidosis II	Phase 2/3
DNL343 + Matching Placebo	Amyotrophic Lateral Sclerosis	Phase 2/3
tividenofusp alfa + idursulfase	Mucopolysaccharidosis II	Phase 2/3
DNL126	Mucopolysaccharidosis Type IIIA	Phase 1/2
tividenofusp alfa	Mucopolysaccharidosis II	Phase 1/2

Funding History

Total raised: $910M

PIPE$400MFidelity InvestmentsJun 15, 2020

IPO$250MUndisclosedDec 7, 2017

Series B$130MFidelity InvestmentsFeb 15, 2017

Series A$130MARCH Venture PartnersMar 15, 2015

Opportunities

Denali's primary growth opportunities lie in the successful clinical validation and commercialization of its TransportVehicle™ platform.

Positive Phase 3 data in Parkinson's (DNL151) and MPS II (DNL310) could lead to blockbuster products and validate the platform for broader application.

This would enable expansion into other neurodegenerative and lysosomal storage diseases, as well as potential out-licensing of the platform technology to other biopharma companies.

Risk Factors

Key risks include the high clinical failure rate inherent in CNS drug development, particularly for novel mechanisms and delivery platforms.

The company's valuation is heavily dependent on a few late-stage clinical readouts.

Furthermore, Denali faces intense competition from large pharma and other biotechs in neurodegenerative diseases, and its financial sustainability relies on continued capital markets access and partnership milestones.

Competitive Landscape

Denali competes with large pharmaceutical companies (Biogen, Roche, Eli Lilly) and biotechs in neurodegenerative diseases, and with companies like BioMarin and Sanofi in lysosomal storage disorders. Its primary differentiation is the TransportVehicle™ platform, which aims to solve the fundamental challenge of blood-brain barrier penetration for large-molecule drugs—a key limitation for many competitors' approaches.

Publications

Patents

Pipeline